NASDAQ:AMRS - Amyris Stock Price, Forecast & News

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Amyris's stock reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

Amyris Inc (NASDAQ:AMRS) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.02. The biotechnology company had revenue of $34.95 million for the quarter, compared to the consensus estimate of $21.60 million. View Amyris' Earnings History.

Amyris is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Amyris.

Amyris issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$150 million, compared to the consensus revenue estimate of $$148.65 million.

2 Wall Street analysts have issued twelve-month price targets for Amyris' shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate Amyris' share price to reach $9.50 in the next year. This suggests a possible upside of 213.5% from the stock's current price. View Analyst Price Targets for Amyris.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.

Media headlines about AMRS stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Amyris earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Amyris.

Amyris saw a increase in short interest in December. As of December 31st, there was short interest totalling 17,190,000 shares, an increase of 11.7% from the December 15th total of 15,390,000 shares. Based on an average daily volume of 1,040,000 shares, the short-interest ratio is presently 16.5 days. Approximately 31.4% of the company's shares are short sold. View Amyris' Current Options Chain.

Some companies that are related to Amyris include Phillips 66 (PSX), Valero Energy (VLO), Marathon Petroleum (MPC), HollyFrontier (HFC), CVR Energy (CVI), PBF Energy (PBF), World Fuel Services (INT), Delek US (DK), Renewable Energy Group (REGI), Clean Energy Fuels (CLNE), REX American Resources (REX), Green Plains (GPRE), Adams Resources & Energy (AE) and Gevo (GEVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Canopy Growth (CGC), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Intel (INTC), Novavax (NVAX), General Electric (GE), Cara Therapeutics (CARA) and Inovio Pharmaceuticals (INO).

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMRS stock can currently be purchased for approximately $3.03.

Amyris has a market capitalization of $319.67 million and generates $80.42 million in revenue each year. The biotechnology company earns $-230,240,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. Amyris employs 414 workers across the globe.View Additional Information About Amyris.

The official website for Amyris is http://amyris.com/.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]